Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

207P - Does age affect PD-L1 expression? Results of a single-center analysis of a large cohort of patients

Date

31 Mar 2023

Session

Poster Display session

Presenters

Magdalena Knetki-Wroblewska

Citation

Journal of Thoracic Oncology (2023) 18 (4S): S149-S153.
<article-id>elcc_Ch10

Authors

M. Knetki-Wroblewska1, P. Wisniewski2, A. Szatkowska-Tomczyk2, J. Owczarek2, M. Krzakowski2, M. Prochorec-Sobieszek2

Author affiliations

  • 1 Warsaw/PL
  • 2 Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw/PL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 207P

Background

Tumor-programmed death ligand 1 (PD-L1) expression is a key biomarker analyzed in patients diagnosed with advanced non-small cell lung cancer (NSCLC). It is important to determine the real-world prevalence of PD-L1 expression and indicate differences in clinically relevant patient subgroups-including the elderly population.

Methods

Samples of patients (pts) who qualified for the first-line treatment of advanced NSCLC in 2017–2022 were analyzed. Immunohistochemistry was performed using the PD-L1 kit (PD-L1 IHC 22C3 pharmDX; Dako). Descriptive analysis, applying chi-square test to compare PD-L1 categories between groups, and logistic regression to calculate odds ratios were performed.

Results

A samples of 1710 pts were analyzed. The median age was 68 years, 34.5% of pts were <65 while 17.3% were >75 years old. The prevalence of squamous-cell carcinoma in the entire population was 35.7%, adenocarcinoma 51.5%, NOS 2.7% and other types 10.1%. PD-L1 expression ≥50% was found in 33.3% of pts, while 1–49% and <1% in 23.8% and 42.8% of pts, respectively. In 5% of the cases, no reliable test result was obtained due to insufficient cellularity of specimens (<100). PD-L1 expression <1% was observed more frequently in patients with non-squamous carcinoma (46.3% vs 37.1%; p = 0.001). Other variables - gender and type of sample (excisional biopsy, thick needle biopsy) - of the entire population, had no impact on the prevalence of PD-L1 expression. Additional analysis was performed in subgroups in relation to age. In the group of patients >65 years of age, no differences were observed for expression levels >1% (p = 0.280) and >50% (p = 0.368), similarly in the group of patients >75 years of age – p = 0.169 and p = 0.882, respectively. However, subgroup analysis indicated a higher probability of <1% expression in patients >65 years of age with a diagnosis of non-squamous carcinoma (OR 0.65, p = 0.00; 95% CI 0.49–0.85).

Conclusions

Analysis of a large cohort of patients indicated an association between non-squamous cancer type in elderly pts and a higher incidence of PD-L1 <1% expression. In 5% of analyzed pts, tests were not feasible. Alternative diagnostic methods for PD-L1, including soluble forms of biomarkers, are needed.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M. Knetki-Wroblewska: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Roche, MSD, Takeda, Amgen, AstraZeneca, Boehringer Ingelheim, Ipsen; Financial Interests, Personal, Advisory Board: Takeda, Boehringer Ingelheim, Bristol Myers Squib. P. Wiśniewski: Financial Interests, Personal, Invited Speaker: MSD. M. Krzakowski: Financial Interests, Personal, Advisory Board: MSD, Roche, AstraZeneca, BMS, Amgen; Financial Interests, Personal, Other, Travel grant: Roche, AstraZeneca. M. Prochorec-Sobieszek: Financial Interests, Personal, Invited Speaker: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.